Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Ligand Pharmaceuticals reported a robust financial performance with a 48% growth in royalty revenue for the full year 2025, leading to total revenues of $268.1 million, up from $167.1 million in 2024 [1][7] - The company reaffirmed its financial guidance for 2026, expecting revenues between $245 million and $285 million, with adjusted earnings per diluted share projected at $8.00 to $9.00 [1][11] Financial Performance - For Q4 2025, total revenues were $59.7 million, a 39% increase from $42.8 million in Q4 2024, primarily driven by a 45% rise in royalty revenue to $50.5 million [3][5] - Full year 2025 royalty revenues reached $161.0 million, compared to $108.8 million in 2024, attributed to increased sales of key products [7][10] - GAAP net income for Q4 2025 was $44.8 million, or $2.12 per diluted share, a significant recovery from a net loss of $31.1 million, or $1.64 per share, in Q4 2024 [5][10] Cost and Expenses - Research and development expenses for Q4 2025 were $3.5 million, down from $4.4 million in Q4 2024, while general and administrative expenses slightly decreased to $25.0 million from $25.6 million [4][9] - For the full year 2025, R&D expenses surged to $81.2 million from $21.4 million in 2024, largely due to one-time charges related to royalty financing agreements [9][10] Cash Position - As of December 31, 2025, Ligand had cash, cash equivalents, and short-term investments totaling $733.5 million, a significant increase from $256.2 million in 2024 [6][32] Business Highlights - The company highlighted the successful out-licensing and partner launch of Zelsuvmi, contributing to the strong financial results [2] - Recent product developments include positive clinical results for Filspari and Ohtuvayre, with significant sales growth reported for Filspari [12][13] Future Outlook - Ligand's 2026 financial guidance includes expected royalty revenue of $200 million to $225 million, sales of Captisol between $35 million and $40 million, and contract revenue of $10 million to $20 million [11]